Diversify Advisory Services LLC Increases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Diversify Advisory Services LLC boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,331 shares of the biopharmaceutical company’s stock after purchasing an additional 418 shares during the period. Diversify Advisory Services LLC’s holdings in Halozyme Therapeutics were worth $305,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. TD Asset Management Inc raised its position in Halozyme Therapeutics by 28.1% in the first quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after purchasing an additional 557,350 shares during the period. Boston Trust Walden Corp purchased a new position in Halozyme Therapeutics in the second quarter valued at about $23,211,000. CANADA LIFE ASSURANCE Co raised its position in Halozyme Therapeutics by 29.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 130,856 shares of the biopharmaceutical company’s stock valued at $5,321,000 after purchasing an additional 29,845 shares during the period. Swedbank AB purchased a new position in Halozyme Therapeutics in the first quarter valued at about $13,927,000. Finally, Mizuho Markets Americas LLC raised its position in Halozyme Therapeutics by 2.2% in the first quarter. Mizuho Markets Americas LLC now owns 456,636 shares of the biopharmaceutical company’s stock valued at $18,576,000 after purchasing an additional 9,975 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Down 0.0 %

NASDAQ:HALO opened at $50.57 on Friday. The company has a market capitalization of $6.41 billion, a price-to-earnings ratio of 19.60, a price-to-earnings-growth ratio of 0.50 and a beta of 1.27. Halozyme Therapeutics, Inc. has a one year low of $33.07 and a one year high of $65.53. The stock has a 50-day simple moving average of $57.32 and a 200 day simple moving average of $51.82. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. The business had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period last year, the firm earned $0.68 earnings per share. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total value of $525,800.00. Following the transaction, the chief executive officer now owns 676,744 shares of the company’s stock, valued at $35,583,199.52. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total value of $525,800.00. Following the transaction, the chief executive officer now owns 676,744 shares of the company’s stock, valued at $35,583,199.52. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the transaction, the director now directly owns 69,874 shares in the company, valued at $4,031,729.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 89,881 shares of company stock valued at $5,169,834 over the last quarter. Insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on HALO shares. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price objective for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. TD Cowen raised their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Wells Fargo & Company downgraded Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Finally, The Goldman Sachs Group raised their target price on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.44.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.